The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome

International Urology and Nephrology

Volumn 34, Issue 4, 2002, Pages 495-501

  Babjuk, Marko ^a   Soukup, V ^a   Mares J ^a   Duskova J ^a   Sedlacek Z ^a   Trkova M ^a   Pecen, L ^b   Dvoracek J ^a   Hanus T ^a   Kocvara R ^a   Novak J ^a   Povysil C ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF COMPUTER SCIENCE   (Czech Republic)

Author keywords

HSCORE; p53 immunohistochemistry; p53 mutation analysis; PAX5 gene; Superficial bladder TCC

Indexed keywords

BCG VACCINE; MESSENGER RNA; MITOMYCIN C; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DO1; PROLINE; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; EXON; FEMALE; GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PAIRED BOX GENE 5; PROGNOSIS; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SEQUENCE ANALYSIS; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

AGED; CARCINOMA, TRANSITIONAL CELL; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0141991732     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025652203472     Document Type: Article

References (30)

1. Abdel-Fattah R, Challen C, Griffiths TRL et al. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998; 77: 2230-2238.
2. Adshead JM, Ogden CW, Penny MA et al. The expression of PAX5 in human transitional cell carcinoma of the bladder: Relationship with de-differentiation. British J Urol International 1999;83:1039-1044.
3. Bártek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893-899.
4. Berggren P, Steineck G, Adolfsson J et al. p53 mutations in urinary bladder cancer. Br J Cancer 2001; 84: 1505-1511.
5. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletions of a tumor suppressor gene on chromosome 9. Oncogene 1993; 8: 1083-1085.
6. Cordon-Cardo C, Dalbagni G, Saez GT et al. p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 1994; 56: 347-353.
7. Esrig D, Spruck ChH, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389-1397.
8. Gardiner RA, Walsh MD, Allen V et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 1993; 73: 526-532.
9. Gontero P, Casetta G, Zitella A et al. Evaluation of p53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000; 38: 287-296.
10. Grompe M (1993). The rapid detection of unknown mutations in nucleic acids. Nat Genet 1993; 5: 111-117.
11. Heney NM, Ahmed S, Flanaghan MJ et al. Superficial bladder cancer: Progression and recurrence. J Urol 1983; 130: 1083-1086.
12. Kozmik Z, Sure U, Rüedi D et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci 1995; 92: 5709-5713.
13. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573-580.
14. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
15. Llopis J, Alcaraz A, Ribal MJ et al. p53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol 2000; 37: 644-653.
16. Maulbecker CC, Gruss P. The oncogenic potential of Pax genes. EMBO J 1993; 12: 2361-2397.
17. Mc Carty KS Jr, Miller LS, Cox EB et al. Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.
18. Nutt SL, Thevenin C, Busslinger M. Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiol 1997;198:227-235.
19. Orlow I, Lianes P, Lacombe L et al. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res 1994; 54: 2848-2851.
20. Reiher F, Ozer O, Pins M et al. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol 2002; 167: 1469-1474.
21. Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993; 85: 53-59.
22. Schmitz-Dräger BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000; 38: 691-700.
23. Sedláček Z, Kodet R, Kříž V et al. Two Li-Fraumeni syndrome families with novel germline p53 mutations: Loss of the wild type allele in only 50% of tumours. Brit. J. Cancer 1998; 77: 1034-1039.
24. Serth J, Kuczyk MA, Bokmeyer C et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995; 71: 201-205.
25. Shigyo M, Sugano K, Fukayama N et al. Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end single-strand DNA conformation polymorphism. Int J Cancer 1998; 78: 425-429.
26. Sobin LH, Wittekind C. UICC TNM Classification of Malignant Tumours, 5th ed. New York: Wiley Liss, 1997: 187-190.
27. Spruck CH, Ohneseit P, Gonzalez-Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784-788.
28. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. The EMBO Journal 1995; 14: 5638-5645.
29. Stuart ET, Kioussi Ch, Aguzzi A, Gruss P. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clinical Cancer Res 1995; 1: 207-214.
30. Urbánek P, Wang Z-Q, Fetka I et al. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 1994; 79: 901-912.